San Diego-based TRACON Pharmaceuticals announced that the U.S FDA has granted TRC105 orphan drug designation for the treatment of patients with soft tissue sarcoma.  Sarcomas are rare tumors that originate from mesenchymal tissues (e.g., bone, cartilage, fat and muscle). In the U.S., the incidence of soft tissue sarcomas is approximately 13,000 new cases per year, leading to approximately 5,000 deaths annually.

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic disease.  TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors.